GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endocyte Inc (NAS:ECYT) » Definitions » Shares Buyback Ratio %

Endocyte (Endocyte) Shares Buyback Ratio % : -69.92 (As of May. 05, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Endocyte Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Endocyte's current shares buyback ratio was -69.92%.

Endocyte Shares Buyback Ratio % Historical Data

The historical data trend for Endocyte's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endocyte Shares Buyback Ratio % Chart

Endocyte Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.66 -15.57 - -1.42 -13.75

Endocyte Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.94 -0.72 -44.03 -0.82 -16.18

Endocyte Shares Buyback Ratio % Calculation

Endocyte's Shares Buyback Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2016 ) - Shares Outstanding (EOP) (A: Dec. 2017 )) / Shares Outstanding (EOP) (A: Dec. 2016 )
=(42.3775 - 48.2035) / 42.3775
=-13.75%

Endocyte's Shares Buyback Ratio for the quarter that ended in Sep. 2018 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2018 ) - Shares Outstanding (EOP) (A: Sep. 2018 )) / Shares Outstanding (EOP) (A: Jun. 2018 )
=(69.9961 - 81.3233) / 69.9961
=-16.18%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endocyte Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Endocyte's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Endocyte (Endocyte) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endocyte Inc (NAS:ECYT) » Definitions » Shares Buyback Ratio %
Comparable Companies
SZSE:002603 XKRX:086900 SZSE:300294 DNLI INSM ZLAB AKCA ZGNX ICPT RGNX LGND OSTO:VITR APLS PTLA BOM:539268 LSE:GNS BOLD TSE:4565 XLRN EBS
Traded in Other Exchanges
N/A
Address
Website
http://www.endocyte.com
Endocyte Inc is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases using precision medicine. Precision medicine is a medical discipline seeking to treat diseased cells with minimal impact on healthy cells. The company uses its proprietary technology to create novel small-molecule drug conjugates and companion imaging agents. The company's therapeutic areas are non-small cell lung, breast, colorectal, kidney, endometrial, prostate, and ovarian cancers; solid tumors; polycystic kidney disease; and inflammation.
Executives
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
John C Aplin director ONE AMERICAN SQUARE STE 2850, INDIANAPOLIS IN 46282
David R. Mcavoy officer: General Counsel C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Alison A. Armour officer: Chief Medical Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Marc D Kozin director
Michael T. Andriole officer: Chief Financial Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Beth Taylor officer: VP Finance & Chief Acctg Off 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Michael A. Sherman director, officer: President and CEO 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fred A Middleton director 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Peter D Meldrum director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Chandra D Lovejoy officer: VP of Regulatory Affairs C/O PRONAI THERAPEUTICS, INC. 2150 - 885 WEST GEORGIA ST VANCOUVER A1 V6C 3E8
David D. Meek officer: Chief Commercial Officer 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906